Advances in understanding and managing rosacea: Part 1 - Connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 3, 2012, Pages 16-25

  Del Rosso, James Q ^a,b,c  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR;

CLINICAL FEATURE; DEMODEX; ERYTHEMATOTELANGIECTATIC ROSACEA; FACE ERYTHEMA; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; MEMBRANE PERMEABILITY; PAPULOPUSTULAR ROSACEA; PATHOPHYSIOLOGY; PHOTODERMATOSIS; REVIEW; ROSACEA; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; STRATUM CORNEUM; SYMPTOMATOLOGY;

EID: 84860353132     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Marks R. The enigma of rosacea. J Dermatolog Treat. 2007;18:326-328. (Pubitemid 350223201)
2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341. (Pubitemid 39178655)
3. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
4. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100. (Pubitemid 44433118)
5. Sapadin AN, Fleischmajer R. Tetracyclines: non-antibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265. (Pubitemid 43144395)
6. Bevins CL, Liu FT. Rosacea: skin innate immunity gone awry? Nat Med. 2007;13:904-906. (Pubitemid 47222032)
7. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13: 975-980. (Pubitemid 47222043)
8. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77-81.
9. Fleischer AB Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
10. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2-11.
11. Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23.
12. Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-47.
13. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
14. Rosina P, Zamperetti M, Giovannini A, et al. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol. 2006;54:100-104. (Pubitemid 41832465)
15. Jang YH, Sim JH, Kang HY, et al. Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea. J Eur Acad Dermatol Venereol. 2011;25:544-548.
16. Wilkin J, Dahl M, Detmar M, et al. Standard classification system of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
17. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2004;50:907-912. (Pubitemid 38685771)
18. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12-15.
19. De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
20. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-1672. (Pubitemid 38057748)
21. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-850.
22. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22:287-294.
23. Gomaa AH, Yaar M, Eyada MM, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34:748-753. (Pubitemid 47459684)
24. Guzman-Sanchez DA, Ishiuji Y, Patel T, et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57:800-805. (Pubitemid 47553073)
25. Huggenberger R, Detmar M. The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc. 2011;15:24-32.
26. Tjabringa GS, Aarbiou J, Ninaber DK, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol. 2003;171:6690-6696. (Pubitemid 37532101)
27. Tokumaru S, Sayama K, Shirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175:4662-4668. (Pubitemid 41362007)
28. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180:1141-1146. (Pubitemid 24256627)
29. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206. (Pubitemid 32927782)
30. Steinhoff M, Ständer S, Seelinger S, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139:1479-1488.
31. Cevikbas F, Steinhoff A, Homey B, Steinhoff M. Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol. 2007;7:365-373. (Pubitemid 47415278)
32. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2011;9:21-25.
33. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688-697.
34. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141. (Pubitemid 38932283)
35. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(Suppl 3):28-31, 32-34.
36. Torok HM. Rosacea skin care. Cutis. 2000;66(Suppl 4):14-16.
37. McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63:33-39.
38. Martin DB, Gaspari AA. Toll-like receptors. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:67-84.
39. Hansen C, Leitenberger JJ, Jacobe HT, et al. Photoimmunology. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:147-155.
40. Chung J, Cho S, Kang S. Why does the skin age? Intrinsic aging, photoaging, and their pathophysiology. In: Rigel DS, Weiss RA, Lim HW, Dover JS, eds. Photoaging. New York: Marcel Dekker; 2004:1-13.
41. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol. 1998;37:263-266. (Pubitemid 28189686)
42. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life Sci. 2008;65:2019-2038.
43. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009;284:32989-32994.
44. Lefkove BA, Fried LE, Arbiser JL. Angiogenesis for the clinician. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:157-168.
45. Oztas MO, Balk M, Ogüs E, et al. The role of free radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192. (Pubitemid 36459629)
46. Tisma VS, Basta-Juzbasic A, Jaganjac M, et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol. 2009;60:270-276.
47. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
48. Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111:864-872. (Pubitemid 28509331)
49. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004;31:618-626. (Pubitemid 39243784)
50. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775-777. (Pubitemid 29514037)
51. Larios G, Alevizos A, Perimeni D, et al. Rosacea-like demodicidosis. Lancet Infect Dis. 2008;8:804.
52. Segal R, Mimouni D, Feuerman H, et al. Dermoscopy as a diagnostic tool in demodicidosis. Int J Dermatol. 2010;49:1018-1023.
53. Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2:20-25.
54. Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Dermatol Venereol. 2005;19:646-647. (Pubitemid 41742858)
55. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
56. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
57. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthetic Dermatol. 2008;1:20-25.
58. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
59. Elias PM. The skin barrier as an innate immune element. Semin Immunopathol. 2007;29:3-14. (Pubitemid 47596384)